Daniel Shelly

Yaklaşan katılımlar

• 4th Cell Therapy for Autoimmune Disease Summit 2026

  1–3 Dec 2026Philadelphia, United States of America

  • ÇalıştayMorning Workshop: Moving Beyond CD19 to Identify the Next-Generation of Clinically Viable Targetsİle: Thimmaiah Chendrimada
  • KonuşmacıDriving Treg Cell Therapy Innovation via T-Cell Targeting, Multi-Editing, and In Vivo Antigen Specific Tregs

Geçmiş katılımlar

• 11th CAR-TCR Summit 2026

  15–17 Sept 2026Boston, United States of America

  • PanelC-Level Think Tank: Scale Readiness Across Modalities

Şu etkinlikteki diğer konuşmacılar: 4th Cell Therapy for Autoimmune Disease Summit 2026

• Fred Aslan

  President & Chief Executive Officer, Artiva Biotherapeutics, Inc

• Rena Baek

  Executive Director, Preclinical Development, Moderna

• Michael Mingueneau

  Vice President, Immunology, Sail Biomedicines

• Edward Zhang

  Co-Founder & Chief Executive Officer, Overland Therapeutics

• Mark Bach

  Chief Medical Officer, GentiBio

• Nathalie Belmonte

  Chief Science & Technical Officer, Quell Therapeutics

Etkinlik sayfasında 21 konuşmacının tümünü gör

Şu etkinlikteki diğer konuşmacılar: 11th CAR-TCR Summit 2026

• James Adams

  Chief Technical Officer, Tr1x therapeutics

• Stephan Krause

  Executive Director, Analytical Strategy, Cell Therapy Global Quality, Bristol Myers Squibb

• Michael Mingueneau

  Vice President, Immunology, Sail Biomedicines

• Nikhil Mutyal

  Head of Search and Evaluation - Respiratory and Immunology, AstraZeneca

• Luke Pase

  Chief Technology Officer, Anocca AB

• Hong Xin

  Senior Director, Oncology Scientific Innovation, Johnson & Johnson

Etkinlik sayfasında 83 konuşmacının tümünü gör